Company profile: Genprex
1.1 - Company Overview
Company description
- Provider of clinical-stage immunogene therapies and diabetes gene therapy candidates: REQORSA for non-small and small cell lung cancer using the ONCOPREX nanoparticle system to deliver the TUSC2 tumor suppressor gene; GPX-002 for Type 1 Diabetes via AAV delivery of Pdx1 and MafA to convert alpha cells to beta-like cells; and GPX-003 for Type 2 Diabetes targeting beta cell replenishment.
Products and services
- GPX-002: AAV-based diabetes gene therapy that delivers Pdx1 and MafA to the pancreas, reprogramming alpha cells into insulin-producing beta-like cells for Type 1 Diabetes
- GPX-003: Beta-cell–targeted diabetes gene therapy candidate engineered to replenish and rejuvenate pancreatic beta cells in Type 2 Diabetes patients, aiming to restore endogenous insulin production
- REQORSA Immunogene Therapy: Nanoparticle-enabled gene therapy for NSCLC and SCLC, using the ONCOPREX delivery system to administer the TUSC2 tumor suppressor gene
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Genprex
EpiBiome
HQ: United States
Website
- Description: Provider of precision microbiome engineering focused on developing alternatives to small-molecule antibiotics for use in healthcare, veterinary, and agriculture industries to address antibiotic resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EpiBiome company profile →
Swift Biosciences
HQ: United States
Website
- Description: Provider of molecular biology reagents for research and diagnostic applications; based in Ann Arbor, Michigan.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Swift Biosciences company profile →
OncoMark
HQ: Ireland
Website
- Description: Provider of companion diagnostic tests for cancer patient stratification. An Irish UCD spin-out, the company develops diagnostics to support cancer drug development, enabling pharmaceutical companies to select patients for whom a drug may be particularly effective, and tests that can also be used during clinical trials to help reduce the numbers of patients required.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoMark company profile →
Scipher Medicine
HQ: United States
Website
- Description: Provider of a healthcare platform to determine which drug will work best for each patient, offering PrismRA, a blood test that predicts non-response to TNF inhibitors in rheumatoid arthritis; Spectra, a platform that discovers novel drug targets by analyzing patient molecular data and the human interactome; and PrismUC, a diagnostic test for ulcerative colitis utilizing molecular data to guide treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scipher Medicine company profile →
Gnubio
HQ: United States
Website
- Description: Provider of scalable desktop DNA sequencing systems for diagnostic and applied markets, integrating target selection, DNA amplification, sequencing, and analysis via emulsion-based droplet microfluidics. Offers single-use consumable cartridges and workflows for targeted sequencing and hotspot analysis, with whole genome and transcriptome applications in development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gnubio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Genprex
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Genprex
2.2 - Growth funds investing in similar companies to Genprex
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Genprex
4.2 - Public trading comparable groups for Genprex
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →